GenStar Therapeutics Appoints Creighton W. Lawhead as Senior Vice President and Chief Business Officer
SAN DIEGO--(BUSINESS WIRE)--June 27, 2002--GenStar Therapeutics (Amex: GNT) announced today the appointment of Creighton W. Lawhead, MBA as senior vice president and chief business officer. The Company also announced today that Lee R. McCracken, former president and chief business officer, has left the company and Robert E. Sobol, M.D., chief executive officer will assume the additional responsibilities of president.
"We are very pleased that Creighton has agreed to join our executive management team," stated Dr. Robert E. Sobol. "Creighton brings an extensive background in business development and investor relations, which will be of great value to GenStar Therapeutics. We have appreciated Lee's service to GenStar, and look forward to his ongoing contributions as an advisor to the company."
Mr. Lawhead adds 28 years of diversified business development, investor relations, marketing and sales experience to GenStar's management team. Mr. Lawhead previously served as vice president and head of commercial affairs and investor relations for The Immune Response Corporation. During Mr. Lawhead's tenure over the past eight years, The Immune Response Corporation received over $100 million in revenues as a result of the completion of 12 corporate partnerships. In addition, Mr. Lawhead held previous senior management positions with Eli Lilly & Company (Hybritech, Inc.), Wyeth, and Boehringer Mannheim. Mr. Lawhead received his MBA from the University of Massachusetts. |
